We hypothesize that patients in the RA risk group have raised biomarkers associated with atherosclerosis and thereby possibly already have an increased risk for cardiovascular disease in comparison with ACPA positive individuals with only joint complaints. This evidence concerns the gene PRTN3 and atherosclerosis.